69. Kinoshita N, Goebl M, Yanagida M (1991)
The fission yeast dis3+ gene encodes a
110-kDa essential protein implicated in
mitotic control. Mol Cell Biol 11
(12):5839–5847
70. Kim DU, Hayles J, Kim D, Wood V, Park
HO, Won M, Yoo HS, Duhig T, Nam M,
Palmer G, Han S, Jeffery L, Baek ST, Lee H,
Shim YS, Lee M, Kim L, Heo KS, Noh EJ,
Lee AR, Jang YJ, Chung KS, Choi SJ, Park JY,
Park Y, Kim HM, Park SK, Park HJ, Kang EJ,
Kim HB, Kang HS, Park HM, Kim K, Song K,
Song KB, Nurse P, Hoe KL (2010) Analysis of
a genome-wide set of gene deletions in the
fission yeast Schizosaccharomyces pombe.
Nat Biotechnol 28(6):617–623
71. Hou D, Ruiz M, Andrulis ED (2012) The
ribonuclease Dis3 is an essential regulator of
the developmental transcriptome. BMC
Genomics 13:359
72. Lim SJ, Boyle PJ, Chinen M, Dale RK, Lei EP
(2013) Genome-wide localization of exosome
components to active promoters and chroma-
tin insulators in Drosophila. Nucleic Acids
Res 41(5):2963–2980
73. Rudnik-Scho¨neborn S, Senderek J, Jen JC,
Houge G, Seeman P, Puchmajerova A,
Graul-Neumann L, Seidel U,
Korinthenberg R, Kirschner J, Seeger J,
Ryan MM, Muntoni F, Steinlin M,
Sztriha L, Colomer J, Hubner C,
Brockmann K, Van Maldergem L, Schiff M,
Holzinger A, Barth P, Reardon W,
Yourshaw M, Nelson SF, Eggermann T,
Zerres K (2013) Pontocerebellar hypoplasia
type 1: clinical spectrum and relevance of
EXOSC3 mutations. Neurology 80
(5):438–446
74. Eggens VR, Barth PG, Niermeijer JM, Berg
JN, Darin N, Dixit A, Fluss J, Foulds N,
Fowler D, Hortobagyi T, Jacques T, King
MD, Makrythanasis P, Mate A, Nicoll JA,
O’Rourke D, Price S, Williams AN,
Wilson L, Suri M, Sztriha L, Dijns-de Wissel
MB, van Meegen MT, van Ruissen F,
Aronica E, Troost D, Majoie CB, Marquering
HA, Poll-The BT, Baas F (2014) EXOSC3
mutations in pontocerebellar hypoplasia type
1: novel mutations and genotype-phenotype
correlations. Orphanet J Rare Dis 9(1):23
75. Lohr JG, Stojanov P, Carter SL, Cruz-
Gordillo P, Lawrence MS, Auclair D,
Sougnez C, Knoechel B, Gould J,
Saksena G, Cibulskis K, McKenna A, Chap-
man MA, Straussman R, Levy J, Perkins LM,
Keats JJ, Schumacher SE, Rosenberg M, Mul-
tiple Myeloma Research Consortium, Getz G,
Golub TR (2014) Widespread genetic
heterogeneity in multiple myeloma: implica-
tions for targeted therapy. Cancer Cell 25
(1):91–101
76. Weissbach S, Langer C, Puppe B, Nedeva T,
Bach E, Kull M, Bargou R, Einsele H,
Rosenwald A, Knop S, Leich E (2015) The
molecular spectrum and clinical impact of
DIS3 mutations in multiple myeloma. Br J
Haematol 169(1):57–70
77. Walker BA, Boyle EM, Wardell CP,
Murison A, Begum DB, Dahir NM, Proszek
PZ, Johnson DC, Kaiser MF, Melchor L,
Aronson LI, Scales M, Pawlyn C,
Mirabella F, Jones JR, Brioli A,
Mikulasova A, Cairns DA, Gregory WM,
Quartilho A, Drayson MT, Russell N,
Cook G, Jackson GH, Leleu X, Davies FE,
Morgan GJ (2015) Mutational spectrum,
copy number changes, and outcome: results
of a sequencing study of patients with newly
diagnosed myeloma. J Clin Oncol 33
(33):3911–3920
78. Lionetti M, Barbieri M, Todoerti K,
Agnelli L, Fabris S, Tonon G, Segalla S,
Cifola I, Pinatel E, Tassone P, Musto P,
Baldini L, Neri A (2015) A compendium of
DIS3 mutations and associated transcriptional
signatures in plasma cell dyscrasias. Oncotar-
get 6(28):26129–26141
79. Zanni G, Scotton C, Passarelli C, Fang M,
Barresi S, Dallapiccola B, Wu B, Gualandi F,
Ferlini A, Bertini E, Wei W (2013) Exome
sequencing in a family with intellectual dis-
ability, early onset spasticity, and cerebellar
atrophy detects a novel mutation in
EXOSC3. Neurogenetics 14(3-4):247–250
80. Halevy A, Lerer I, Cohen R, Kornreich L,
Shuper A, Gamliel M, Zimerman BE,
Korabi I, Meiner V, Straussberg R, Lossos A
(2014) Novel EXOSC3 mutation causes com-
plicated hereditary spastic paraplegia. J
Neurol 261(11):2165–2169
81. Oddone A, Lorentzen E, Basquin J, Gasch A,
Rybin V, Conti E, Sattler M (2007) Structural
and biochemical characterization of the yeast
exosome component Rrp40. EMBO Rep 8
(1):63–69
82. Walker BA, Wardell CP, Melchor L, Hulkki S,
Potter NE, Johnson DC, Fenwick K,
Kozarewa I, Gonzalez D, Lord CJ,
Ashworth A, Davies FE, Morgan GJ (2012)
Intraclonal heterogeneity and distinct molec-
ular mechanisms characterize the develop-
ment of t(4;14) and t(11;14) myeloma.
Blood 120(5):1077–1086
83. Bolli N, Avet-Loiseau H, Wedge DC, Van
Loo P, Alexandrov LB, Martincorena I, Daw-
son KJ, Iorio F, Nik-Zainal S, Bignell GR,
30 Milo B. Fasken et al.